Hit enter to search or ESC to close

An Alternate Future

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.

Improving lives.

Our history

Alterity Therapeutics was incorporated in Melbourne, Australia in 1997 as Prana Biotechnology and has offices in Melbourne, Australia, and San Francisco, USA. The Company listed on the Australian Securities Exchange in 2000 and listed on the NASDAQ in 2002.

The company operates under the ticker codes ASX: ATH and NASDAQ: ATHE

Management/Executive Team

Visual Portfolio, Posts & Image Gallery for WordPress

Board of Directors

Geoffrey Kempler, Chairman & FounderB.Sc. Grad. Dip. App. Soc. Psych
Mr Kempler has served as Chairman of our Board of Directors since November 1997, between November 1997 and August 2004 he served as our Chief Executive Officer and again assumed the position of Chief Executive Officer from June 2005 until January 2021. Mr. Kempler is one of the founders of our company.


Mr. Kempler is a qualified psychologist with extensive experience in investment and business developmentand has been responsible for the implementation of our strategic plan and the commercialisation of our technology. Mr. Kempler holds a B.Sc degree in science from Monash University, Grad. Dip. App. Soc. Psych. degree from Swinburne University, and is on the Monash Institute of Cognitive and Clinical Neurosciences (MICCN) Industry Advisory Board. Mr Kempler was appointed as a Non-Executive Chairman of Opthea Limited, an ASX listed drug development company developing innovative, biologics-based therapies for the treatment of eye diseases, on November 30, 2015.

Lawrence Gozlan, Non-Executive DirectorB.Sc. (Hons)
Mr Gozlan was appointed as a director of our company on August 8, 2011. Mr. Gozlan, a leading biotechnology investor and advisor, is the Chief Investment Officer and Founder of Scientia Capital, a specialised global investment fund focused exclusively in life sciences. The Company was founded to provide high level expertise and to manage investments for high net worth individuals, family offices and institutional investors wanting exposure to the biotechnology industry.

Prior to this, Mr Gozlan was responsible for the largest biotechnology investment portfolio in Australia as the institutional biotechnology analyst at QIC (“the Queensland Investment Corporation”), an investment fund with over AU$60 billion under management. He previously worked as the senior biotechnology analyst in the equities team at Foster Stockbroking, and gained senior corporate finance experience advising life science companies at Deloitte.


Mr. Gozlan is currently a Director of Opthea Limited, an ASX listed drug development company and AusBiotech, which is the Australian Biotechnology Industry body and a number of private biotechnology companies in the USA.  He holds a Bachelor of Science with Honors in microbiology and immunology from the University of Melbourne specializing in neurodegenerative diseases.

Peter Marks, Non-Executive DirectorBEc LLB Grad. Dip. Comm. Law MBA
Mr Marks has served as a director of Alterity since July 2005.  He is an experienced company director with significant corporate advisory and investment experience. In his roles with these various financial institutions, Mr. Marks was responsible for advising a substantial number of listed and unlisted companies on issues ranging from corporate and company structure, to valuation, business strategies, acquisitions and international opportunities.


For over 13 years until the end of August 2014, Mr. Marks was a Director of investment bank Peregrine Corporate Ltd, and is currently Chairman of Newburyport Partners, a boutique corporate and capital markets advisory firm specializing in advising small to mid-cap companies.


Mr Marks is currently a non-executive Director of  Electriq Global Ltd, and also currently serves as Director of Noxopharm Ltd, an ASX listed biotechnology company, and Noxopharm subsidiary, Nyrada Inc.

Brian Meltzer, Non-Executive DirectorB. Com., M Ec.
Mr Meltzer has served as a director of our company since December 1999.  Subsequent to several years as Chief Economist of ICI Australia (now Orica), Mr Meltzer spent 25 years in investment banking.  His breadth of expertise includes major property transactions, corporate advisory, corporate finance, management buyouts, venture capital and large scale syndications.


Mr. Meltzer has held a number of Board and Board Advisory roles for private companies in the human resources, health, aged care, software, entertainment and finance sectors, including Director of a federal government licensed Innovation Investment Fund.  Mr. Meltzer is also a director on the board of the Australian-Israel Chamber of Commerce and is Chairman of Independence Australia (previously Paraquad).


He is Chairman of the Audit Committee and member of the Remuneration Committee.

Receive news from Alterity Therapeutics